natgillin/translations-raw huggingface dataset:
The process according to claim 2, wherein the decarboxylation reaction is carried out in a solvent selected from water, toluene, xylene, ethylbenzene, chlorobenzene, dichlorobenzene, nitrobenzene, N,N -dimethyl formamide (DMF) and 1-methyl-2-pyrrolidone (NMP) and at the reflux temperature of said solvent. 
Postupak prema zahtjevu 2, naznačen time, da se dekarboksilacijska reakcija provodi u otapalu odabranom od sljedećih: voda, toluen, ksilen, etilbenzen, klorobenzen, diklorobenzen, nitrobenzen, N,N-dimetil-formamid (DMF) i 1-metil-2-pirolidon (NMP) te na temperaturi refluksa navedenog otapala.
and resolving the resulting diastereomeric mixture via crystallization to provide the compound of formula (II). 
te od rastavaranja rezultirajuće dijastereomerne smjese putem kristalizacije, za dobivanje spoja formule (II).
is C6-C10-aryl, such as phenyl, and "*" means a chiral center with absolute stereochemistry (R) or (S), with an acidic reagent to provide the compound of formula (I). 
je C6-C10-aril, kao što je fenil, i “*” znači kiralni centar s apsolutnom stereokemijom (R) ili (S), s kiselinskim reagensom, za dobivanje spoja formule (I).
The process according to claim 9, wherein the acidic reagent is an inorganic acid or an organic acid, such as hydrochloric acid, sulfuric acid, phosphoric acid, oxalic acid, citric acid, formic acid or acetic acid. 
Postupak prema zahtjevu 9, naznačen time, da kiselinski reagens je anorganska kiselina ili organska kiselina, kao što je klorovodična kiselina, sumporna kiselina, fosforna kiselina, oksalna kiselina, limunska kiselina, mravlja kiselina ili octena kiselina.
The use according to claim 17, wherein the compound is N-(3-carboxy-1-oxopropyl)-(4S)-p-phenylphenylmethyl)-4-amino-(2R)-methylbutanoic acid or a salt or acid ester, thereof. 
Uporaba prema zahtjevu 17, naznačena time, da spoj je N-(3-karboksi-1-oksopropil)-(4S)-(p-fenilfenilmetil)-4-amino-(2R)-metil-butanska kiselina ili njezina sol ili ester te kiseline.
The system according to Claim 3 characterized in that it utilizes the plasma converter (44) fed with high-energy plasma stream from a plasma generator with temperature of 3000-8000°C. 
Sustav prema zahtjevu 3, naznačen time, da koristi plazma konverter (44) koji se napaja plazma tokom visoke energije energijom iz generatora plazme sa temperaturom od 3.000-8.000°C.
The system according to Claim 3 characterized in that it utilizes the converter-plasma furnace (32) with external arc operating at temperature of 2000-5000 C in nitrogen atmosphere, equipped with a cyclone system for interception of dusts. 
Sustav prema zahtjevu 3, naznačen time, da koristi plazma konverter peć (32) s vanjskim lukom koji radi na temperaturi od 2.000-5.000 °C u atmosferi dušika, opremljenom sustavom za ciklonsko hvatanje praha.
The system according to Claim 3 characterized in that it utilizes the gasifier-plasma furnace (40) with internal arc with temperature of 3000-5000°C and oxygen-free temperature, equipped with cyclone system for interception of dusts. 
Sustav u skladu s patentnim zahtjevom 3, naznačen time, da koristi plazma peć za uplinjavanje (40) s unutarnjim lukom i temperaturom od 3000-5000°C i atmosferom bez kisika, opremljenom sustavom za ciklonsko hvatanje praha.
adding at least one water soluble lithium compound to the aqueous preparation in an amount such that the total amount of solubilised lithium in the aqueous preparation is from 1000 to 3000 ppm, calculated relative to the weight of water in the preparation, wherein the water soluble lithium compound is a polymeric salt of lithium selected from Li2Na2polyphosphate or lithium-sodium hexametaphosphate, where steps (a) and (b) may be carried out simultaneously, or separately in any order and wherein the stabilization leads to a reduction of the cfu/ml value to a value of less than 104 cfu/ml. 
dodavanje barem jednog litijevog sastojka topljivog u vodi u vodeni pripravak u količini tolikoj da je ukupna količina otopljenog litija u vodenom pripravku od 1000 do 3000 ppm, izračunato u odnosu na težinu vode u pripravku, pri čemu je litijev spoj topljiv u vodi polimerna sol litija izabrana od Li2Na2polifosfata ili litij-natrij heksametafosfata, gdje koraci (a) i (b) mogu biti izvedeni istovremeno, ili odvojeno bilo kojim redoslijedom te pri čemu stabilizacija dovodi do smanjenja vrijednosti cfu/mL na vrijednost manju od 104 cfu/mL,
Process according to any of claims 1 to 12, wherein said natural calcium carbonate, synthetic, precipitated calcium carbonate, kaolin, talcum, aluminium hydroxide, aluminium silicate, titanium dioxide or mixtures thereof, is natural and/or synthetic calcium carbonate. 
Postupak u skladu s bilo kojim od patentnih zahtjeva 1 do 12, pri čemu je navedeni prirodni kalcijev karbonat, sintetski, istaloženi kalcijev karbonat, kaolin, talk, aluminijev hidroksid, aluminijev salicilat, titanijev dioksid ili njihova smjesa odabran između prirodnog i/ili sintetskog kalcijevog karbonata.
as a biocidal composition in an aqueous preparation comprising strains of bacteria selected from the group consisting of Methylobacteria and Pseudomonas which are resistant to, tolerant to and/or degrade aldehyde-releasing biocides and/or biocides with one or more aldehyde groups in absence of lithium ions. 
kao biocidni sastav u vodenom pripravku koji sadrži sojeve bakterija odabranih iz skupine koja se sastoji od Methylobacteria i Pseudomonas koji su otporni na, tolerantni na i/ili razgrađuju navedene biocide koji otpuštaju aldehid i/ili biocide s jednom ili više aldehidnih skupina u odsustvu iona litija.
The use according to claim 15, wherein the solubilised lithium is in the form of lithium ions. 
Uporaba u skladu s patentnim zahtjevom 15, pri čemu je otopljeni litij u obliku litij iona.
The use according to claims 15 and 16, wherein the aqueous preparation is a dispersion or suspension of natural calcium carbonate, synthetic, precipitated calcium carbonate, kaolin, talcum, aluminium hydroxide, aluminium silicate, titanium dioxide or mixtures thereof, fillers or pigments. 
Uporaba u skladu s patentnim zahtjevom 15 i 16, pri čemu je vodeni pripravak disperzija ili suspenzija prirodnog kalcijevog karbonata, sintetskog, istaloženog kalcijevog karbonata, kaolina, talka, aluminijevog hidroksida, aluminijevog silikata, titanijevog dioksida ili njihovih smjesa, punila ili pigmenata.
wherein the at least one source of a water soluble lithium compound is a polymeric salt of lithium selected from Li2Na2polyphosphate or lithium-sodium hexametaphosphate. 
pri čemu je barem jedan izvor litijevog spoja topljivog u vodi polimerna litijeva sol izabrana od Li2Na2polifosfata ili litij-natrij heksametafosfata.
Composition according to any of claims 18 to 22, wherein at least 40 mole-%, preferably 45 to 80 mole-% and more preferably 95 to 100 mole-%, of the acid sites of said polymeric salts of lithium are neutralized by lithium. 
Sastav u skladu s bilo kojim od patentnih zahtjeva 18 do 22, pri čemu je najmanje 40 mol-%, poželjno 45 do 80 mol-% i poželjnije 95 do 100 mol-% kiselinskih mjesta navedenih polimernih soli litija neutralizirano litijem.
The compound according to claim 1, which is a pharmaceutically acceptable salt of the compound of formula in particular a hydrochloride salt. 
Spoj u skladu s patentnim zahtjevom 1, naznačen time što je farmaceutski prihvatljiva sol spoja formule [image] osobito hidrokloridna sol.
any protecting groups of the resulting compound are removed to yield a compound of formula (II) or a salt thereof and, if so desired, 
sve zaštitne skupine u dobivenom spoju se ukloni kako bi se dobio spoj formule (II), ili njegova sol, i, ako se želi,
reacting a compound of formula with an alpha-amino acid derivative of the formula: in the presence of an activating agent and optionally in the presence of suitable bases, catalysts or co-reagents to yield the compound of formula: 
reakcije spoja formule [image] s derivatom a-aminokiseline formule: [image], u prisutnosti aktivacijskog sredstva i izborno u prisutnosti pogodnih baza, katalizatora ili sureagensa kako bi se dobilo spoj formule:
reacting the product of Step (a) with a bromination agent to yield the bromo compound of formula: 
reakcije produkta iz koraka (a) s bromirajućim sredstvom kako bi se dobilo bromirani spoj formule:
removing any protection groups being present from the group "protected Amino acid" to yield the compound of formula (II-G) and, optionally, 
uklanjanja svih zaštitnih skupina prisutnih u skupini "zaštićena Aminokiselina" kako bi se dobilo spoj formule (II-G) i, izborno,
"Amino acid" represents a residue derived from Glycine, Alanine or Lysine by removing the carboxyl group from the alpha-carbon atom of said amino acid; and "protected Amino acid" means the same amino acid as "Amino acid", primary amino groups and if required also other functional groups of said amino acid however being protected by a protecting group, the prefix "lower" denoting a linear or branched radical having from 1 to 7 carbon atoms. 
-G je skupina formule [image] "Aminokiselina" predstavlja ostatak kojeg se izvodi iz glicina, alanina ili lizina uklanjanjem karboksilne skupine s atoma a-ugljika u navedenoj aminokiselini; i "zaštićena Aminokiselina" znači ista aminokiselina kao "Aminokiselina", no čije su primarne amino skupine i, po potrebi, druge funkcionalne skupine u navedenoj aminokiselini zaštićene zaštitnom skupinom, gdje prefiks "niži" označuje nerazgranati ili razgranati radikal s od 1 do 7 atoma ugljika.
collecting or receiving a sample of lipid tissue containing the stem cells; 
uzimanje ili dobivanje uzorka masnog tkiva koji sadrži matične stanice;
washing the sample of step (a) with a suitable aqueous buffer; 
ispiranje uzorka iz koraka (a) prikladnim vodenim puferom;
incubating the sample of step (b) with an enzyme capable to digest the lipid tissue and extract therefrom the stem cells; 
inkubacija uzorka iz koraka (b) pomoću enzima koji može razgraditi masno tkivo i iz njega ekstrahirati matične stanice;
purifying the aqueous phase obtained in step (d); 
pročišćavanje vodene faze dobivene u koraku (d);
titrating the aqueous phase obtained in step (e) and, if necessary, diluting it to obtain a final stem cell fraction with desired concentration and volume wherein the stem cells-containing material is treated within a syringe throughout at least the steps: (a), (b), and (c), said syringe performing the functions of collecting means, phase separator and process reactor. 
titracija vodene faze dobivene u koraku (e) i, ako je potrebno, razrjeđivanje radi dobivanja konačne frakcije matičnih stanica željene koncentracije i volumena gdje se materijal koji sadrži matične stanice obrađuje unutar štrcaljke barem kroz korake: (a), (b) i (c), ta štrcaljka ima funkcije sredstva za uzimanje, separatora faza i reaktora postupka.
Process according to claims 1-2, wherein the syringe is provided with one or more marks to indicate the optimal filling volume(s), and/or with areas for writing or labelling. 
Postupak prema zahtjevima 1-2, gdje štrcaljka ima jednu ili više oznaka koje pokazuju optimalni volumen(e) punjenja i/ili ima područja za pisanje ili označavanje.
Process according to claims 1-3, wherein the lipid material is a lipoaspirate. 
Postupak prema zahtjevima 1-3, gdje je masni materijal lipoaspirat.
Process according to claims 1-4, wherein the step (a) and (b-d) respectively, are performed by two different operators at locations remote from each other. 
Postupak prema zahtjevima 1-4, gdje se koraci (a), odnosno (b-d) provode od strane dva različita operatera na međusobno udaljenim lokacijama.
Process according to claims 1-5, wherein in step (b) the buffer is a PBS buffer supplemented with enzyme nutrients. 
Postupak prema zahtjevima 1-5, gdje u koraku (b) pufer je PBS pufer s dodacima enzimskih nutrijenata.
Process according to claims 1-6, in which the steps (b) and/or (c) include orienting the syringe downwards (needle down) or upwards (needle up), followed by ejecting the phase proximal to the needle. 
Postupak prema zahtjevima 1-6, gdje koraci (b) i/ili (c) obuhvaćaju okretanje štrcaljke prema dolje (igla prema dolje) ili prema gore (igla prema gore), nakon čega slijedi izbacivanje faze koja se nalazi uz iglu.
Process according to claims 1-9, where the stem cells-containing material is further maintained within the said syringe during one or more of the steps (d)-(e). 
Postupak prema zahtjevima 1-9, gdje se materijal s matičnim stanicama dalje održava unutar štrcaljke tijekom jednog ili više od koraka (d)-(e).
Process according to claims 1-10, wherein purification in step (e) is performed by centrifugation(s) and/or filtration(s). 
Postupak prema zahtjevima 1-10, gdje se pročišćavanje u koraku (e) provodi centrifugiranjem(ima) i/ili filtracijom(ama).
A composition comprising rapamycin and mifepristone, salts, enantiomers or racemates thereof, for simultaneous, separate or sequential administration to a mammalian subject. 
Sastav koji obuhvaća baklofen, D-sorbitol i naltrekson, soli, enantiomere, ili njihove racemate, za istovremenu, odvojenu ili primjenu u slijedu na subjektu sisavcu.
Use of a composition comprising: one or more aldehyde-releasing biocides and/or biocides with one or more aldehyde groups in an amount such that the total amount of aldehyde-releasing biocides and/or biocides with one or more aldehyde groups in the aqueous preparation is from 250 ppm to 5000 ppm, calculated relative to the weight of water in the preparation, and 
dodavanje u vodeni pripravak jednog ili više biocida koji otpušta aldehid i/ili biocida s jednom ili više aldehidnih skupina u tolikoj količini da je ukupna količina biocida koji otpuštaju aldehid i/ili biocida s jednom ili više aldehidnih skupina u vodenom pripravku od 250 ppm do 5000 ppm, izračunata u odnosu na vodu u pripravku;
The use according to any of claims 1 to 3, wherein the biocide with one or more aldehyde groups is selected from the group comprising formaldehyde, acetaldehyde, glyoxal, glutaraldehyde, 2-propenal, phthalic dialdehyde and mixtures thereof, and preferably is formaldehyde, glutaraldehyde or a mixture thereof. 
Postupak u skladu s bilo kojim od patentnih zahtjeva 1 do 5, pri čemu je biocid s jednom ili više aldehidnih skupina odabran iz grupe koja obuhvaća formaldehid, acetaldehid, glioksal, glutaraldehid, 2-propenal, ftalni dialdehid i njihove smjese, poželjno formaldehid, glutaraldehid ili njihova smjesa.
The use according to any of claims 1 to 5, wherein the aldehyde-releasing biocide and/or biocide with one or more aldehyde groups is added to the aqueous preparation in an amount of from 750 ppm to 4000 ppm, preferably in amount of from 1500 ppm to 3000 ppm, calculated relative to the weight of water in the preparation. 
Postupak u skladu s bilo kojim od patentnih zahtjeva 1 do 8, pri čemu se biocid koji otpušta aldehid i/ili biocid s jednom ili više aldehidnih skupina dodaje u vodeni pripravak u količini od 750 ppm do 4000 ppm, poželjno u količini od 1500 ppm do 3000 ppm, izračunato u odnosu na težinu vode u pripravku.
Process according to any of claims 7 or 8, wherein the biocide with one or more aldehyde groups is selected from the group comprising formaldehyde, acetaldehyde, glyoxal, glutaraldehyde, 2-propenal, phthalic dialdehyde and mixtures thereof, and preferably is formaldehyde, glutaraldehyde or a mixture thereof. 
Sastav u skladu s patentnim zahtjevom 18, pri čemu je biocid s jednom ili više aldehidnih grupa odabran iz grupe koja obuhvaća formaldehid, acetaldehid, glioksal, glutaraldehid, 2-propenal, ftalni dialdehid i njihove smjese, i poželjno je formaldehid, glutaraldehid ili njihova smjesa.
The composition of any one of the preceding claims, for use in treating Charcot Marie Tooth disease ("CMT"), a toxic neuropathy or amyotrophic lateral sclerosis (ALS). 
Sastav iz bilo kojeg od prethodnih patentnih zahtjeva, za uporabu u liječenju Charcot Marie Tooth („CMT“) bolesti, toksične neuropatije ili amiotrofične lateralne skleroze („ALS“) u subjekta sisavca.
The vapor-permeable shoe according to claim 1, characterized in that said monolithic sheet-like structure is stratified and cohesive, comprising a plurality of functional layers made of polymeric material which are impermeable to water in the liquid state and permeable to water vapor. 
Paropropusna cipela u skladu s patentnim zahtjevom 1, naznačena time, da je navedena monolitna lisnata struktura slojevita i kohezivna, sadrži veći broj funkcionalnih slojeva izrađenih od polimernog materijala koji su nepropusni za vodu u tekućem stanju, a propusni za vodenu paru.
The vapor-permeable shoe according to claim 4, characterized in that said structural insert (14), which is structured as an assembly insole, is reinforced at the plantar arch by a shank made of a material selected among leather, felt and metallic material. 
Paropropusna cipela u skladu s patentnim zahtjevom 4, naznačena time, da je navedeni strukturni umetak (14), koji je strukturiran kao spojni uložak, pojačan na plantarnom luku držačem načinjenim od materijala odabranog između kože, filca i metalnog materijala.
The vapor-permeable shoe according to claim 8, characterized in that said supporting element (202) is made of a material selected among a mesh made of polymeric material, a mesh made of metallic material, felt, leather. 
Paropropusna cipela u skladu s patentnim zahtjevom 8, naznačena time, da je navedeni potporni element (202) izrađen od materijala odabranog između mrežice načinjene od polimernog materijala, mrežice načinjene od metalnog materijala, filca, kože.
The vapor-permeable shoe according to claim 11, characterized in that said sole (12) comprises at least one filler (304), which is vapor-permeable or diffusely perforated and lies below said functional element. 
Paropropusna cipela u skladu s patentnim zahtjevom 11, naznačena time, da navedeni potplat (12) sadrži najmanje jedno punjenje (304), koje je paropropusno ili difuzno perforirano i leži ispod navedenog funkcionalnog elementa.
a vapor-permeable upper (16), a vapor-permeable upper lining (17), arranged so as to line said upper (16) internally to the foot insertion region (A), 
paropropusna podstava gornjišta (17), postavljena tako da oblaže navedeno gornjište (16) iznutra prema području umetanja stopala u cipelu (A),
a sealing film (21) made of thermoplastic adhesive material being provided which covers the region of connection of said lower edge (22a) to said structural insert (14), so as to mutually seal them, 
koristi se brtvena folija (21) koja je načinjena od termoplastičnog ljepljivog materijala, koja obuhvaća područje spajanja navedenog donjeg ruba (22a) na spomenuti strukturni umetak (14), na način da ih međusobno hermetički zatvara,
a sealing film (21) made of thermoplastic adhesive material being provided which covers the region of connection of said lower edge (22a) to said structural insert (14), so as to mutually seal them, 
koristi se brtvena folija (21) načinjena od termoplastičnog ljepljivog materijala, koja obuhvaća područje spajanja navedenog donjeg ruba (22a) na spomenuti strukturni umetak (14), na način da ih međusobno hermetički zatvara,
has haemophilia A, and is undergoing, or is about to undergo, factor VIII replacement therapy; or 
ima hemofiliju A, te se podvrgava, ili će biti podvrgnut, nadomjesnom liječenju faktora VIII; ili
has, or is at risk from contracting, acquired haemophilia. 
ima, ili je u opasnosti od nastanka, stečene hemofilije.
The method as claimed in claim 1, wherein in the step of mixing the PRP with the calcium chloride solution, about 1 ml of the PRP collected through a process of separating the PRP from the whole blood is mixed once with the calcium chloride solution with a concentration of 0.30-0.55 mg/mL by three way connector. 
Postupak prema zahtjevu 1, naznačen time, da u koraku miješanja PRP-plazme s otopinom kalcijevog klorida, odjednom se miješa oko 1 ml od sakupljene PRP-plazme s otopinom kalcijevog klorida tijekom postupka odvajanja PRP-plazme od sveukupne krvi, s koncentracijom od 0,30 do 0,55 mg/mL, pomoću konektora s tri priključka.
leaving the type I collagen at room temperature; 
ostavljanje kolagena tipa I na sobnoj temperaturi;
mixing the mixture of the PRP and the calcium chloride solution with the type I collagen with a concentration of 20-50 mg/mL, in an opaque phase, four times through connection by three way connector; and injecting the mixture of the PRP and the type I collagen, charged in a syringe, into all regions in need of tissue regeneration in cases such as bone defect treatment and wound healing. 
miješanje smjese PRP-plazme i otopine kalcijevog klorida s kolagenom tipa I u koncentraciji od 20 do 50 mg/mL, u neprozirnoj fazi, četiri puta kroz spajanje pomoću konektora s tri priključka; i injektiranje mješavine PRP-plazme i kolagena tipa I, koja se ispušta sa štrcaljkom u sva područja koja trebaju obnavljanje tkiva u slučajevima liječenja oslabljenih kostiju i kod zacjeljivanja rana.
The method as claimed in claim 3, wherein the type I collagen is left at room temperature for 15 to 30 minutes. 
Postupak prema zahtjevu 3, naznačen time, da se kolagen tipa I ostavlja 15 do 30 minuta na sobnoj temperaturi.
A method for managing the automatic provision of a subscriber network identifier from a central network server (108) to a subscribed communication device (10), the method comprising: 
Postupak za upravljanje automatskim osiguravanjem pretplatničke mrežne identifikacije sa centralnog mrežnog servera (108) pretplatničkom komunikacionom uređaju (10), pri čemu ovaj postupak obuhvaća:
receiving notification (200) at the central server relating to a change in the current location for the subscribed device; 
prijem notifikacije (200) na centralnom serveru koja se odnosi na promjenu trenutne lokacije pretplatničkog uređaja;
The method of Claim 1 or Claim 2, wherein the receiving step comprises receiving a notification from an HLR scanner, the HLR scanner being arranged to detect a location update message received by a Home Location Register (111), abbreviated as HLR, to which the subscribed device is subscribed, the location update message corresponding to the change in current location of the subscribed device. 
Postupak prema zahtjevu 1 i zahtjevu 2, pri čemu prijemni korak obuhvaća prijem notifikacije od HLR skenera, a HLR skener je podešen da detektira poruku o promjeni lokacije koju prima Registar Vlastitih Pretplatnika (engl. Home Location Register) (111), skraćeno HLR, na koji je pretplatnički uređaj pretplaćen, pri čemu poruka o promjeni lokacije odgovara promjeni trenutne lokacije pretplatničkog uređaja.
The method of Claim 3, wherein the HLR is not associated with a specific physical network infrastructure for radio communication with subscribed devices. 
Postupak prema zahtjevu 3, pri čemu HLR nije povezan sa posebnom fizičkom mrežnom infrastrukturom za radio komunikaciju sa pretplatničkim uređajima.
The method of Claim 3 or Claim 4, wherein the determining step comprises: retrieving an IMSI list from the HLR for the subscribed device, the IMSI list comprising all of the IMSIs which are allocated to the subscribed device; and 
dobivanje IMSI liste od HLR-a za pretplatnički uređaj, pri čemu IMSI lista obuhvaća sve IMSI-je koji su pridruženi pretplatničkom uređaju; i određivanje da li IMSI lista obuhvaća IMSI koji je odgovarajući za trenutnu lokaciju pretplatničkog uređaja.
The method of claim 5, wherein the step of determining whether an IMSI is appropriate is based on previously determined preferences for the subscribed device. 
Postupak prema zahtjevu 5, pri čemu je korak za određivanje da li je IMSI odgovarajući baziran na prethodno određenim preferencama pretplatničkog uređaja.
The method of Claim 8, wherein the outputting step further comprises outputting a set of rules concerning when the local IMSI is to be used by the subscribed device. 
Postupak prema zahtjevu 8, pri čemu izlazni korak dalje obuhvaća slanje skupa pravila koja se odnose na to kada je lokalni IMSI za upotrebu na pretplatničkom uređaju.
The method of Claim 8 or Claim 9, wherein the outputting step further comprises outputting a corresponding MSISDN for the selected IMSI. 
Postupak prema zahtjevu 8 i zahtjevu 9, pri čemu izlazni korak dalje obuhvaća slanje odgovarajućeg MSISDN za odabrani IMSI.